Kornimate/medical-research-clean huggingface dataset:
effect of aerobic interval training on cardiovascular function in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the study objectives are: 1. to compare cardiovascular function in type 2 diabetes patients vs. healthy controls. 2. to compare the effect of 8 weeks of aerobic interval training versus continuous moderate exercise on cardiovascular function in adults with type 2 diabetes. 3. to examine the mechanisms underlying the exercise-related changes in cardiovascular function. the investigators hypothesize that compared to continuous moderate intensity exercise training, interval training will be more effective in improving cardiovascular function in adults with type 2 diabetes.

cardiovascular function will be measured at baseline in adults with type 2 diabetes and in age-matched healthy controls. research volunteers with type 2 diabetes who meet the inclusion criteria will be randomized to the aerobic interval training group, continuous moderate exercise group or non-exercise control group. at the end of the 8-week randomized control exercise intervention, baseline measures will be repeated.

Eligibility criteria:
inclusion criteria for type 2 diabetes : * diagnosis of type 2 diabetes * sedentary or minimally physically active for at least the prior 1 year * able to give consent inclusion criteria for healthy control group: * sedentary or minimally physically active for at least the prior 1 year * able to give consent exclusion criteria: * history of diabetic proliferative retinopathy, autonomic or peripheral neuropathy * history of any relevant cardiovascular diseases (myocardial infarction, angina pectoris, history of coronary artery bypass surgery or angioplasty, congestive heart failure, or arrhythmia) * hypertension (≥160 mmhg systolic or ≥100 mmhg diastolic) * history of renal impairment * history of gout or hyperuricemia * history of hepatic disease or infection with hepatitis b, c * history of seizures, or other relevant on-going or recurrent illness * recent (within 3 months) or recurrent hospitalizations * use of tobacco products * \>5 % weight change in the prior 6 months. * current intake of medications that may affect study results * premenopausal women taking oral contraceptives and postmenopausal women taking hormone replacement therapy. * pregnancy (positive urine pregnancy test) or lactation * for the healthy control group, history of diabetes.
a novel method for retrograde intrarenal surgery (rirs)

Conditions: Kidney Stone

Summary: in this prospective randomised controlled study, investigators aims to evaluate the effect of 80 mg gentamicin added to 3 liters of irrigation fluid on stone free rate, intraoperative and postoperative complications during rirs for kidney stones.

current advances in endoscopic technology for the upper urinary tract have expanded the diagnosis and treatment options for kidney stones. retrograde intrarenal surgery (rirs), defined as the use of effective lithotripters such as flexible ureteroscopes (furss) and holmium:yttrium aluminum garnet (holmium:yag) lasers for intrarenal pelvic diseases, is a safe and effective, versatile and minimally invasive procedure for the kidney. . current guidelines for the treatment of kidney stones recommend rirs first for stones \ 2 cm.. in studies dealing with kidney stones larger than 2 cm, the rirs showed a cumulative stone-free success of 91%, but a complication rate of 8.6%. of these, 44% were found to be ≥ clavien 3 complications. in kidney stone endourological treatments, stone culture was found to be more effective in predicting complications than midstream urine culture. even if the preoperative midstream urine culture is sterile, complication rates increase if there is bacterial growth in the stone culture in kidney stone surgery. therefore, although complication rates are generally low, several concerns have arisen. in our study, the investigators aims to evaluate the effect of 80 mg gentamicin added to 3 liters of irrigation fluid on stone free rate and complications during rirs for kidney stones.

Eligibility criteria:
inclusion criteria: * \<2 cm. kidney stones exclusion criteria: * ureteral stricture * active urinary tract infection * coagulopathies
pharmacokinetics of chiglitazar in subjects with renal impairment and normal renal function

Conditions: Renal Impairment

Summary: this phase 1 open label study is being conducted to directly characterize the pharmacokinetic (pk) profiles of chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with normal renal function.


Eligibility criteria:
inclusion criteria: * voluntarily sign informed consent, able to comply with the requirements of the study. * male or female, between 18 and 79 years of age. * 18≤bmi≤30. weight of male ≥50 kg and weight of female ≥ 45 kg. * no medication within 2 weeks, or stable medication for at least 4 weeks prior to screening. * the absolute egfr must meet standard in renal function classification. * physical examination, vital signs examination, 12-lead electrocardiogram (ecg) examination, and laboratory test have been determined by the investigator to be suitable for participating in this trial, and serum potassium ≥3.5 mmol/l and ≤5.5 mmol/l. exclusion criteria: * allergic constitution, or allergic to ppar agonist drugs or any component of chiglitazar tablets. * received ppar agonist drugs within 2 weeks before screening. * those who have been vaccinated within 4 weeks before screening, or who plan to be vaccinated during the trial. * positive test for covid-19. * suffer from uncontrolled serious diseases of heart failure/hypertension, respiratory, liver, gastrointestinal, endocrine, blood, mental/nervous systems within 1 year before screening. * have previously undergone surgery that may affect the absorption, distribution, metabolism, and excretion of drugs; anticipate surgery or hospitalization during the trial. * drug abusers within 5 years before screening., or positive test for drugs of abuse. * smoking more than 5 cigarettes per day on average within 3 months before screening. * the average daily alcohol intake in the 3 months prior to screening exceeds the following criteria: more than 14 g for women, or more than 28 g for men; ingested any products containing alcohol within 48 hours before administration; positive alcohol breath test. * ingestion of grapefruit juice/grapefruit juice, food or drink rich in methylxanthine within 48 hours before administration; strenuous exercise or other factors that affect drug absorption, distribution, metabolism, excretion. * participated in clinical trials of any drug or medical device within 3 months before screening. * donated blood (or blood loss) ≥400 ml within 3 months before screening, or have received blood products. * acute hepatitis, chronic liver disease, or any one of alt, ast, and total bilirubin is greater than 2 times the upper limit of normal. * hbsag, hcv antibody, hiv antibody, or tp antibody antibody positive. * female subjects who are breastfeeding or positive test of serum pregnancy. * other circumstances assessed by the investigator are not suitable for participating in this trial.
a study of fabrazyme in pediatric patients with fabry disease

Conditions: Fabry Disease

Summary: people with fabry disease have an alteration in their genetic material (dna) which causes a deficiency of the a-galactosidase a enzyme. this enzyme helps to break down and remove certain types of fatty substances called "glycolipids". these glycolipids are normally present within the body in most cells. in people with fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase a is not present, or is present in small quantities. the build up of glycolipid levels (also referred to as "globotriaosylceramide" or "gl-3") in these tissues is thought to cause the clinical symptoms that are common to fabry disease. symptoms commonly appear during childhood with pain in the hands and feet. this study explored the safety, efficacy and pharmacokinetics of fabrazyme in pediatric patients aged between 7 and 15 years.


Eligibility criteria:
inclusion criteria: * patient or legal guardian must provide written informed consent * patients must have a clinical diagnosis of fabry disease and active fabry disease (clinical signs and symptoms) * patients must be at least 7 years of age but no older than 15 years of age at time of enrollment * patients must be tanner stage ≤ iii * female patients must have a negative pregnancy test prior to each infusion and use a medically accepted form of contraception throughout the study exclusion criteria: * patient has a clinically significant organic disease (with the exception of symptoms relating to fabry disease) that in the opinion of the investigator would preclude participation in the trial * patient has participated in a study employing investigational drug within 30 days of the start of this study * patient has received prior treatment with enzyme replacement therapy * patient is unable to comply with the clinical protocol

Keywords: a-galactosidase a agal r-hagal fabry gl-3 fabrazyme
podcasting hiv prevention within african american communities

Conditions: HIV Prevention

Summary: given the continued impact of hiv among african americans, there is still an urgent need to expand prevention efforts and hiv testing in african american communities. heterosexual individuals may acquire and spread infection directly through heterosexual contact, bi-sexual sexual contact, and/or indirectly through homosexual sexual contact. evidence-based interventions (ebis) have been shown to increase consistent condom use, decrease sexual partners, and increase hiv testing; however, traditionally-implemented ebis may not be accessible to communities given the resources and expertise needed to implement them. this project seeks to: 1) assess feasibility for the development of two theory- based, video podcast-delivered, hiv prevention interventions for self-identified heterosexual african american males and females; and 2) evaluate their feasibility \& effectiveness (pilot). the investigators will develop the two (male and female) video podcasts that maintain the theoretical integrity of two established centers for disease control evidence-based behavioral hiv prevention interventions. the assessment phase will consist of leveraging african american community stakeholders and experts in the development of the podcast content. the effectiveness phase will consist of broadcasting the podcasts for participants and evaluating psychosocial factors related to hiv prevention at 1 and 3 month follow-ups. this intervention is the first of its kind and has the potential to increase hiv protective behaviors in this hard-to-reach and medically underserved population. the resulting interventions are expected to be easily disseminated throughout the african american communities, with the potential to reduce hiv- related disparities within this population. this study will impact and advance the field by demonstrating feasibility and effectiveness for a novel mode of intervention engagement within hiv prevention science, serve as valuable preliminary data for a larger r01 trial, and foster hiv prevention awareness within the african american community.


Eligibility criteria:
inclusion criteria: * self-identify as african american * speak and read english * 18 years old or older * not currently or previously diagnosed with hiv exclusion criteria: • currently or previously diagnosed with hiv

Keywords: hiv prevention african americans health disparities
predictors of bariatric surgery weight loss

Conditions: Obesity, Mild; Obesity, Morbid; Diabete Mellitus; Diabetes Mellitus, Type 2; Eating Disorders

Summary: the aim of the observational cross-sectional study is to determine the prevalence and correlates of disordered eating among candidates for bariatric surgery in the baripredict cohort. the study aims to answer the following question on whether the prevalence of disordered eating is higher in individuals that are candidates of bariatric surgery compared to the general population with obesity.

participants referred to jaber al ahmad al sabah hospital, hawalli, kuwait, for bariatric surgery were consecutively screened for the study. a cross-sectional analysis was performed on a subgroup of this cohort with complete baseline data. the analysis investigates the influence of psychological factors associated with obesity before bariatric surgery.

Eligibility criteria:
inclusion criteria: * obesity bmi \> 30 kg/m2 * 18 years and older exclusion criteria: * bmi \< 30 kg/m2

Keywords: obesity metabolic disease eating disorder mental health
effectiveness of reducing smoking in facilitating smoking cessation in adolescents - 2

Conditions: Smoking Cessation; Tobacco Use Disorder

Summary: currently one in five high school students smoke. smoking can harm adolescents well before they reach adulthood by causing a number of immediate, sometimes irreversible, health risks and problems. this study will examine whether reducing smoking will facilitate quitting smoking in adolescents who have unsuccessfully attempted to quit smoking

among adolescents, the short-term health effects of smoking include damage to the respiratory system, addiction to nicotine, and the associated risk of other drug use. adolescents are at greater risk for long-term health problems, including several types of cancer. this study will examine whether reducing smoking will facilitate smoking cessation in adolescents who have unsuccessfully attempted to quit smoking. the study will also assess whether reduction of smoking leads to continued involvement in treatment, less toxic cigarette exposure, and improved motivation and self-efficacy to quit. participants in this open-label study will undergo 2 weeks of baseline measurements, followed by 2 weeks of smoking cessation treatment. treatment will involve a nicotine patch, for those who are eligible, and a standardized behavioral intervention aimed at supporting smoking cessation. those who are ineligible to receive a nicotine patch will only receive the standardized behavioral intervention. participants who quit smoking during the first phase of treatment will continue to receive the nicotine patches and/or the standardized behavioral intervention. those who are still smoking after the first treatment will be randomly assigned to one of two conditions and will continue to use nicotine patches for 4 weeks. group 1 will receive standardized behavioral therapy and will set a specific quit date. group 2 will be encouraged to decrease smoking by 50% the first week and 75% the second week. during week 3, participants will be encouraged to completely quit smoking. study visits will occur weekly, at which time nicotine patches will be dispensed, standardized behavioral therapy will be provided, and standard physiological measurements will be taken. a urine sample will also be collected. follow-up visits will be held 2 weeks, 3 weeks, and 6 months following completion of the study.

Eligibility criteria:
inclusion criteria: * has smoked at least 5 cigarettes a day for at least 6 months * does not regularly use other tobacco products * motivated to quit smoking * not currently using medications to quit smoking * willing to use an effective form of contraception throughout the study exclusion criteria: * informed that nicotine replacement therapy is medically inadvisable * diagnosed with a psychiatric disorder within 3 months prior to enrollment * currently taking an unstable dose of psychoactive medications * currently taking medications that may react with a nicotine patch * history of alcohol or drug abuse within 3 months prior to enrollment * pregnant

Keywords: smoking addiction
focused versus enhanced cognitive behavioral therapy for treating women with bulimia nervosa

Conditions: Eating Disorders

Summary: this study will compare the effectiveness of two types of cognitive behavioral therapy in treating adult women with the dysregulated subtype of bulimia nervosa.

bulimia nervosa (bn) is a common eating disorder that is characterized by periods of bingeing and purging. people with the dysregulated subtype of bn experience behavioral impulsivity; disruption of cognitive, affective, behavioral, and neurophysiological processes (dysregulation); interpersonal dysfunction; and poor treatment response. to date, no therapies have been tested for this specific population, and it is unknown whether therapy that directly focuses on treating bn symptoms or one that addresses both eating and personality disorder symptoms is more effective. cognitive behavioral therapy (cbt), which concentrates on modifying patients' behaviors and ways of thinking, has been effective in treating bn. this study will compare the effectiveness of two types of cbt, focused and broad, in treating adult women with the dysregulated subtype of bn. participants in this single-blind study will be randomly assigned to receive 20 sessions of either broad (enhanced) or focused cbt. participants will meet with a therapist once or twice weekly until 20 sessions have occurred. broad cbt will address symptoms of bn, as well as those of the personality disorder. focused cbt will concentrate only on bn symptoms. before treatment begins, participants will complete a set of questionnaires pertaining to their experiences with bn, depression, anxiety, and interpersonal relationships. the questionnaires will be used throughout the study to assess participants' progress. participants will also attend a clinical interview lasting approximately 3.5 hours. questions will concern bn, other eating disorder symptoms, depression, anxiety, and interpersonal relationships. blood samples and vital signs will also be taken at the time of the clinical interview and as needed later in the treatment process.

Eligibility criteria:
inclusion criteria: * diagnosis of bulimia nervosa * presence of borderline personality disorder features * history of one mood or anxiety episode within 2 years prior to study entry * if taking psychiatric medication, dose has been stable for at least 6 weeks at time of study entry exclusion criteria: * substance dependence * diagnosis of bipolar i disorder * psychosis * mental retardation * receiving psychosocial treatment

Keywords: bulimia nervosa cognitive behavioral therapy personality disorders
analysis of safety and tissue interaction of injectable and energy-based biosmulators

Conditions: This Study Aims to Evaluate the Safety Profile and Tissue Changes After Biostimulatory Treatments to the Face in Healthy Volunteers

Summary: the goal of this clinical trial is to analyse tissue changes in the pre-auricular region after injectable (poly-l-lactic-acid/calcium-hydroxylapatit/ and energy-based (radiofrequency microneedling) biostimulatory interventions in healthy volunteers. the main questions it aims to answer are: how is the safety profile of biostimulatory treatments? how are the tissue interactions after biostiomulatory treatments? participants will: * recieve one of 3 possible biostumulatory treatments (plla/caha/rfm) * attend 5 follow-up appointments after treatment for checkups, surveillance and examinations.

patients undergoing biostimulatory treatments will be invited to participate in this study involving photographic evaluations and ultrasound imaging. following detailed oral and written explanations, patients will provide informed consent. participants will be assigned to one of three treatment groups: 1. plla (sculptra®, sinclair pharmaceuticals) 2. caha (radiesse®, merz pharma; harmonyca®, allergan) 3. rfmn (genius®, lutronic medical systems) treatment protocols: * plla: 1-3 sessions at intervals of 4-6 weeks * caha: single session * rfmn: 1-3 sessions at intervals of 6-8 weeks these interventions will follow routine clinical protocols, with more frequent follow-ups involving photography and ultrasound imaging as part of the study. follow-up assessments patients will undergo follow-up evaluations at 5 defined time points after treatment: 1. 6 weeks 2. 6 months 3. 12 months 4.18 months 5. 24 months

Eligibility criteria:
-inclusion criteria: men and women aged 30 years and older good general health, no relevant pre-existing conditions patients planning to undergo caha, plla, or rfmn treatment as part of routine care due to skin laxity or volume loss cognitive ability and willingness to provide informed consent willingness and ability to attend follow-up visits -exclusion criteria: age under 30 years pregnant or breastfeeding individuals significant open wounds or lesions in the treatment area metallic implants in the treatment area psychiatric disorders (psychosis, body dysmorphic disorders) missing informed consent and/or data privacy declarations

Keywords: ultrasound biostimulation poly-l-lactic-acid calcium-hydroxylapatit radio frequency microneedling
bevacizumab, erlotinib, and imatinib in the treatment of advanced renal cell carcinoma

Conditions: Clear Cell Renal Cell Carcinoma

Summary: this phase i/ii trial will evaluate the bevacizumab/erlotinib combination with the addition of imatinib (gleevec). the combined inhibition greatly enhances the anti-tumor effects. although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been demonstrated, the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity. a brief phase i portion will be included in this trial, to optimize doses of the 3 agents prior to proceeding with the phase ii trial.

upon determination of eligibility, patients will be receive: bevacizumab + erlotinib + imatinib a brief phase i dose escalation study will be performed to define the imatinib dose that will be used.

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * metastatic or unresectable clear cell renal carcinoma confirmed by biopsy * previous nephrectomy is required * maximum of 1 previous systemic regimen for metastatic disease. * able to perform activities of daily living with minimal assistance * measurable disease * adequate bone marrow, liver and kidney * written informed consent. exclusion criteria: * age \< 18 years * treatment with more than 1 previous systemic regimen * history of heart attack within 6 months * clinically significant cardiovascular disease * moderate to severe vascular disease. * active brain metastases. * history or evidence by physical examination of brain tumor * seizures not controlled with standard medical therapy * history of stroke or other serious disorders of the nervous system * clinical history of coughing or vomiting blood within the past 3 months. * peg tubes or g tubes * chronic therapy with nsaids or other platelet inhibitors * proteinuria * nonhealing wound, ulcer, or long bone fracture * clinical evidence or history of a bleeding disorder * requiring full dose anticoagulation with coumadin * receiving chronic steroid therapy * significant medical conditions. * tumors other than clear cell * history of stroke within 6 months. * history of abdominal fistula,perforation,or abscess within 6 months. please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Keywords: recurrent clear cell renal cell carcinoma bevacizumab erlotinib imatinib